Financials Maccura Biotechnology Co.Ltd

Equities

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
11.38 ^CNY	-0.70%		-3.15%	-24.49%

06-27	Maccura Biotechnology Co.Ltd Announces Final Profit Distribution Plan on A Shares for the Year 2023, Payable on July 3, 2024	CI
06-21	Maccura Biotechnology Gets Nod to Register Automatic Biochemical Analyzer	MT

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	15,041	25,961	16,243	10,596	9,230	6,906	-	-
Enterprise Value (EV) ¹	15,041	25,961	16,243	10,596	9,230	6,906	6,906	6,906
P/E ratio	28.6 x	32.7 x	17 x	14.9 x	29.5 x	16.1 x	12.8 x	10.5 x
Yield	0.7%	-	-	-	1.03%	3.08%	4.48%	5.8%
Capitalization / Revenue	4.67 x	7.01 x	4.08 x	2.94 x	3.19 x	2.26 x	2.04 x	1.83 x
EV / Revenue	4.67 x	7.01 x	4.08 x	2.94 x	3.19 x	2.26 x	2.04 x	1.83 x
EV / EBITDA	17.6 x	21.7 x	11.2 x	9.86 x	-	8.6 x	7.22 x	6.16 x
EV / FCF	-	-	-	-	221 x	62.8 x	19.8 x	11.5 x
FCF Yield	-	-	-	-	0.45%	1.59%	5.04%	8.69%
Price to Book	4.81 x	6.84 x	3.78 x	1.68 x	1.45 x	1.03 x	0.97 x	0.9 x
Nbr of stocks (in thousands)	557,699	557,109	556,470	612,470	612,470	606,828	-	-
Reference price ²	26.97	46.60	29.19	17.30	15.07	11.38	11.38	11.38
Announcement Date	24/02/20	25/02/21	19/04/22	24/04/23	24/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	3,223	3,704	3,981	3,608	2,896	3,059	3,377	3,778
EBITDA ¹	854.8	1,198	1,450	1,074	-	803.4	956.5	1,122
EBIT ¹	695.8	989.7	1,214	817.4	331.1	497.4	620.2	753.4
Operating Margin	21.59%	26.72%	30.5%	22.65%	11.44%	16.26%	18.36%	19.94%
Earnings before Tax (EBT) ¹	693.2	969.8	1,187	789.1	305.4	471.9	594.6	728.3
Net income ¹	525.3	793.9	956.6	708	312.6	433.6	544.3	664.4
Net margin	16.3%	21.43%	24.03%	19.62%	10.8%	14.18%	16.12%	17.58%
EPS ²	0.9418	1.424	1.718	1.165	0.5104	0.7067	0.8900	1.087
Free Cash Flow ¹	-	-	-	-	41.78	110	348	600
FCF margin	-	-	-	-	1.44%	3.6%	10.3%	15.88%
FCF Conversion (EBITDA)	-	-	-	-	-	13.69%	36.38%	53.48%
FCF Conversion (Net income)	-	-	-	-	13.37%	25.37%	63.94%	90.31%
Dividend per Share ²	0.1890	-	-	-	0.1550	0.3500	0.5100	0.6600
Announcement Date	24/02/20	25/02/21	19/04/22	24/04/23	24/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	-	-	-	-	41.8	110	348	600
ROE (net income / shareholders' equity)	18%	22.9%	23.1%	12.1%	4.94%	6.41%	7.74%	8.73%
ROA (Net income/ Total Assets)	10.5%	-	-	-	-	-	-	-
Assets ¹	5,026	-	-	-	-	-	-	-
Book Value Per Share ²	5.610	6.820	7.720	10.30	10.40	11.00	11.70	12.60
Cash Flow per Share ²	0.8200	1.960	2.910	1.380	-	0.9700	1.260	1.450
Capex ¹	503	498	600	967	860	695	517	403
Capex / Sales	15.62%	13.43%	15.07%	26.81%	29.69%	22.72%	15.31%	10.68%
Announcement Date	24/02/20	25/02/21	19/04/22	24/04/23	24/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

C+

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.38 CNY

Average target price

15.46 CNY

Spread / Average Target

+35.85%

	1st Jan change	Capi.
MACCURA BIOTECHNOLOGY CO.LTD	-24.49%	950M
BIOMÉRIEUX	-11.78%	11.24B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-13.76%	7.29B
LANTHEUS HOLDINGS, INC.	+29.50%	5.57B
DIASORIN S.P.A.	-0.19%	5.31B
AUTOBIO DIAGNOSTICS CO., LTD.	-19.19%	3.68B
ANDON HEALTH CO., LTD.	+7.62%	2.58B
10X GENOMICS, INC.	-65.24%	2.33B
VITROLIFE AB	-10.48%	2.23B
MYRIAD GENETICS, INC.	+27.80%	2.21B